Discussion:NURS 6521 Flavoxate Hydrochloride
Discussion:NURS 6521 Flavoxate Hydrochloride
Discussion:NURS 6521 Flavoxate Hydrochloride
A patient is taking flavoxate hydrochloride (Urispas) to help control an overactive bladder. On a follow-up visit to the clinic, the nurse will question the patient about which of the following?
PRECAUTIONS
Information for Patients:
Patients should be informed that if drowsiness and blurred vision occur, they should not operate a motor
vehicle or machinery or participate in activities where alertness is required.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of
flavoxate HCl have not been performed.
Pregnancy:
Teratogenic Effects–Pregnancy Category B.
Reproduction studies have been performed in rats and rabbits at doses up to 34 times the human dose and
revealed no evidence of impaired fertility or harm to the fetus due to flavoxate HCl. There are,
however, no well-controlled studies in pregnant women. Because animal reproduction studies are not
always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers:
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human
milk, caution should be exercised when flavoxate HCl is administered to a nursing woman.
Pediatric Us e:
Safety and effectiveness in children below the age of 12 years have not been established.
ADVERSE REACTIONS
The following adverse reactions have been observed, but there are not enough data to support an
estimate of their frequency.
Gastrointestinal: Nausea, vomiting, dry mouth.
CNS: Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.
Hematologic: Leukopenia (one case which was reversible upon discontinuation of the drug).
Cardiovas cular: Tachycardia and palpitation.
Allergic: Urticaria and other dermatoses, eosinophilia and hyperpyrexia.
Ophthalmic: Increased ocular tension, blurred vision, disturbance in eye accommodation.
Renal: Dysuria.
OVERDOSAGE
The oral LD for flavoxate HCl in rats is 4273 mg/kg. The oral LD for flavoxate HCl in mice is
1837 mg/kg.
50 50
It is not known whether flavoxate HCl is dialyzable.
DOSAGE AND ADMINISTRATION
Adults and children over 12 years of age:
One or two 100 mg tablets 3 or 4 times a day. With improvement of symptoms, the dose may be reduced.
This drug cannot be recommended for infants and children under 12 years of age because safety and
efficacy have not been demonstrated in this age group.